Yazan Samhouri MD
@yazansamhouri
Followers
401
Following
392
Statuses
326
Hematologist and Cellular Therapist @ahntoday. Passionate about clinical research and 🎾. @realmadrid fan. Married to @lynnaalnimerMD. tweets ≠medical advise
Pittsburgh, PA
Joined August 2011
Had the privilege of speaking on cellular therapy at the University of Kentucky’s Annual Review of Hematology and Immunotherapy. Incredible discussions, great people, and a fantastic opportunity to catch up with friends. Let’s bring #TILs to Kentucky! 💪🏻 #CellTherapy @AHNtoday
4
1
28
RT @lymphomahub: CONGRESS | #ASH24 | PRESENTATION @DocHutchings, University of Copenhagen shared extended follow-up data from the phase Ib/…
0
13
0
RT @ASH_hematology: Are you feeling revitalized? 🎇 #ASH24 has been an incredible reminder of why we do what we do. The knowledge and insp…
0
10
0
That’s a wrap on #ASH24! A big thank you to @ASH_hematology for an inspiring conference. It was fantastic connecting with friends, collaborators, and colleagues. Now, it's back to Pittsburgh to continue advancing patient care and pushing the field forward!
0
0
1
RT @katiiemylady: Shining bright at @ASH_hematology !Huge congratulations to our amazing residents for their outstanding poster presentatio…
0
2
0
Meaningful use of MRD in #MCL. We probably should not transplant patients with uMRD after induction. #lymsm #ASH2024 @chelseap_DO @AHNhemeonc @HemOncFellows
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did not benefit from consolidative auto-HCT. Follow our live feed for more updates: #lymphoma #lymsm
0
1
3
0
3
0
Great results and well conducted study! It’s convincing enough for me! #lymsm #ASH24 @lymphomahub @AHNhemeonc @HemOncFellows 👏👏
inMIND: R/R FL, Tafa+R2 vs R2, presented by @SehnLaurie , 57% reduction in risk of progression/relapse/death. PFS advantage met. I'm curious on antigen loss data as sequencing for CAR-T will be important. #LBA1 #ASH24 #Lymsm
0
1
5
RT @JOEBENNETTMD: inMIND: R/R FL, Tafa+R2 vs R2, presented by @SehnLaurie , 57% reduction in risk of progression/relapse/death. PFS advanta…
0
3
0
#lymsm #ASH24
@TheEBMT lymphoma working party analysis of auto and allo SCT for PTCL. Given paucity of data, It’s important to see this real world data to support current practice. ASCT in CR1 is important and allo-SCT can save lives in relapsed setting @lymphomahub
0
3
13
#lymsm #ASH24 oral abstract: Duvelisib + Ruxolitinib for PTCL, phase 1. Favorable side effect profile even compared with single agent duvelisib (less pneumonitis). ORR 45%, CR 22%. Great responses in AITL/TFH! @lymphomahub @HemOncFellows @AHNhemeonc
0
2
4
RT @JohnPLeonardMD: We have several scenarios in chronic #lymphomas where A+B is standard and active agent C being added (AB vs ABC) in a P…
0
17
0
- ORR 50.6%. CR 23.8%. mFU 5 mo, mPFS 2.7 mo, mOS 7.2 mo - CRS 39.2%. ICANS 11.2% #ASH24 session 906 Congratulations to our own @CyrusKhann and our star fellow and future @RoswellPark lymphoma faculty @chelseap_DO and other authors @AHNtoday
0
0
1
MCL patients with uMRD6 after induction did not benefit from ASCT in the EA4151 trial. Another ASH to question the role of ASCT in MCL in CR1. Would be curious to see stratification based on TP53. @AHNhemeonc @chelseap_DO @CyrusKhann #latebreakingabstract #ASH24
0
0
0
Impressive results for a phase 3 in second line FL treatment and potentially practice changing since the comparator arm is one of the most common used second line. #latebreakingabtracts #ASH24
0
0
0
Although CIT works well, this will be an excellent fixed duration alternative for our less fit patients #ASH24
0
0
0